学术探索
学术期刊
新闻热点
数据分析
智能评审

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

被引：46
作者：
Chang, H
Qi, XY
Samiee, S
Yi, QL
Chen, C
Trudel, S
Mikhael, J
Reece, D
Stewart, AK
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Lab Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M5G 2M9, Canada
[4] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Biostat, Toronto, ON M5G 2M9, Canada
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 36卷 / 09期
基金：
加拿大健康研究院;
关键词：
multiple myeloma; IgH translocations; 13q deletions; p53; deletions; fluorescence in situ hybridization; autologous stem cell transplantation;
D O I：
10.1038/sj.bmt.1705131
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma ( MM). We evaluated 126 MM patients for t(4; 14) or t(11; 14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. W e demonstrate the significance of genetic-based risk classification that clearly segregate patients into low ( no genetic abnormalities or only t( 11; 14)), intermediate ( any one of the genetic abnormalities other than t( 11; 14)) and high-risk groups ( any two or more of the genetic abnormalities other than t( 11; 14)). High-risk patients do not bene. t from stem cell transplant and should be offered alternative therapies.
引用
收藏
页码：793 / 796
页数：4
相关论文
共 14 条
[1]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[2]   Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].
Avet-Loiseau, H ;
Facon, T ;
Grosbois, B ;
Magrangeas, F ;
Rapp, MJ ;
Harousseau, JL ;
Minvielle, S ;
Bataille, R .
BLOOD, 2002, 99 (06) :2185-2191
[3]  
Avet-Loiseau H, 1999, GENE CHROMOSOME CANC, V24, P9, DOI 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO
[4]  
2-K
[5]   Treatment of multiple myeloma [J].
Barlogie, B ;
Shaughnessy, J ;
Tricot, G ;
Jacobson, J ;
Zangari, M ;
Anaissie, E ;
Walker, R ;
Crowley, J .
BLOOD, 2004, 103 (01) :20-32
[6]   Chromosome translocations in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
ONCOGENE, 2001, 20 (40) :5611-5622
[7]   p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].
Chang, H ;
Qi, C ;
Yi, QL ;
Reece, D ;
Stewart, AK .
BLOOD, 2005, 105 (01) :358-360
[8]   The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant [J].
Chang, H ;
Sloan, S ;
Li, D ;
Zhuang, LH ;
Yi, QL ;
Chen, CI ;
Reece, D ;
Chun, K ;
Stewart, AK .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :64-68
[9]   Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: Comparison with karyotype analysis [J].
Chang, H ;
Li, D ;
Zhuang, LH ;
Nie, E ;
Bouman, D ;
Stewart, AK ;
Chun, K .
LEUKEMIA & LYMPHOMA, 2004, 45 (05) :965-969
[10]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
12